Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension

Table 17

In vitro drug release data of Nebivolol and Nateglinide bilayer tablet.

	Nebivolol (NBL8)	Nateglinide (N9)
Time (min)	% drug release
0.1 N HCl
0	0	0
5	25 ± 3.45	1.8 ± 1.01
10	48 ± 3.37	2.4 ± 1.23
15	69 ± 4.28	3.1 ± 1.21
20	84 ± 4.61	3.6 ± 1.34
25	91 ± 4.02	4.1 ± 1.28
30	97 ± 3.43	4.9 ± 1.46
Time (hrs)	% drug release
0.01 N HCl with 0.5% w/v SLS
1		8 ± 3.46
2		17 ± 3.69
3	—	25 ± 4.29
4	—	36 ± 3.66
5	—	45 ± 3.46
6	—	53 ± 4.32
7	—	64 ± 4.23
8	—	72 ± 3.70
9		80 ± 3.42
10	—	87 ± 4.18
11		91 ± 3.42
12	—	97 ± 3.22